Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 9/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8972502 | 1.00 | GSK3B (0.51) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL8743023 | 1.00 | GSK3B (0.51) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL9167926 | 0.85 | CDK1 (0.42) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL27327838 | 0.83 | GSK3B (0.44) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL9505698 | 0.83 | CDK1 (0.41) | ADORA2AADORA1 | |
| SCHEMBL8927516 | 0.81 | AHCY (0.53) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL27293671 | 0.81 | AHCY (0.53) | GSK3BAHCYADORA2AALDH1A1ADORA1 | |
| SCHEMBL8742956 | 0.77 | BLM (0.48) | ALDH1A1 | |
| SCHEMBL8742951 | 0.77 | BLM (0.48) | ALDH1A1 | |
| SCHEMBL8743090 | 0.77 | BLM (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0184365-B1 | IMPROVEMENTS IN THE TREATMENT OF TUMORS IN MAMMALS | ELI LILLY AND COMPANY (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0368668-B1 | Antibody-drug conjugates | LILLY CO ELI (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5514794-A | DERIVATIZED DRUGS WITH MALONATE LINKER, THE DRUG BEING LINKED THROUGH METHYLENE TO THE 2-POSITION CARBON OF MALONATE; THESE ARE INTERMEDIATES FOR THE CONJUGATES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5464826-A | Antitumor, anticarcinogenic agents, treatment of herpes | ELI LILLY AND COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0184365-B1 | IMPROVEMENTS IN THE TREATMENT OF TUMORS IN MAMMALS | ELI LILLY AND COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5118820-A | Carbohydrate is chemical intermediate for nucleoside | ELI LILLY AND COMPANY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5061793-A | Antitumor agents | ELI LILLY AND COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| US-5015743-A | 2-Deoxy-2,2-difluororibose | ELI LILLY AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| US-5010176-A | Malonate linker | ELI LILLY AND COMPANY (US) | 1991-04-23 | — | — | US | disclosed |
| US-4808614-A | Difluoro antivirals and intermediate therefor | ELI LILLY AND COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0122707-B1 | IMPROVEMENTS IN OR RELATING TO NOVEL DIFLUORO ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4692434-A | NUCLEOSIDES | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0184365-A2 | Improvements in the treatment of tumors in mammals | ELI LILLY AND COMPANY (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4526988-A | Hydrolyzing alkyl 3-dioxolanyl-2,2-difluoro-3-hydroxy propionate | ELI LILLY AND COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0122707-A1 | Improvements in or relating to novel difluoro antiviral agents | ELI LILLY AND COMPANY (US) | 1984-10-24 | — | — | EP | disclosed |